These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27017007)

  • 21. Gut microbiota biomodulators, when the stork comes by the scalpel.
    Miniello VL; Colasanto A; Cristofori F; Diaferio L; Ficele L; Lieggi MS; Santoiemma V; Francavilla R
    Clin Chim Acta; 2015 Dec; 451(Pt A):88-96. PubMed ID: 25668229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies.
    West CE; Renz H; Jenmalm MC; Kozyrskyj AL; Allen KJ; Vuillermin P; Prescott SL;
    J Allergy Clin Immunol; 2015 Jan; 135(1):3-13; quiz 14. PubMed ID: 25567038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications.
    Bober JR; Beisel CL; Nair NU
    Annu Rev Biomed Eng; 2018 Jun; 20():277-300. PubMed ID: 29528686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dynamic microbiome.
    Gerber GK
    FEBS Lett; 2014 Nov; 588(22):4131-9. PubMed ID: 24583074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diet, microbiota, and colorectal cancer.
    Akin H; Tözün N
    J Clin Gastroenterol; 2014; 48 Suppl 1():S67-9. PubMed ID: 25291132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging science of the human microbiome.
    Jones ML; Ganopolsky JG; Martoni CJ; Labbé A; Prakash S
    Gut Microbes; 2014 Jul; 5(4):446-57. PubMed ID: 25013912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthetic microbial consortia: from systematic analysis to construction and applications.
    Song H; Ding MZ; Jia XQ; Ma Q; Yuan YJ
    Chem Soc Rev; 2014; 43(20):6954-81. PubMed ID: 25017039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of pigs as a potential model for research into dietary modulation of the human gut microbiota.
    Heinritz SN; Mosenthin R; Weiss E
    Nutr Res Rev; 2013 Dec; 26(2):191-209. PubMed ID: 24134811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symbiosis, dysbiosis, and rebiosis-the value of metaproteomics in human microbiome monitoring.
    Mao L; Franke J
    Proteomics; 2015 Mar; 15(5-6):1142-51. PubMed ID: 25311577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human microbiome: opportunities and challenges for clinical care.
    Rogers GB
    Intern Med J; 2015 Sep; 45(9):889-98. PubMed ID: 25443179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic modulation of microbiota-host metabolic interactions.
    Holmes E; Kinross J; Gibson GR; Burcelin R; Jia W; Pettersson S; Nicholson JK
    Sci Transl Med; 2012 Jun; 4(137):137rv6. PubMed ID: 22674556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of NMR-based metabolomics to the study of gut microbiota in obesity.
    Calvani R; Brasili E; Praticò G; Sciubba F; Roselli M; Finamore A; Marini F; Marzetti E; Miccheli A
    J Clin Gastroenterol; 2014; 48 Suppl 1():S5-7. PubMed ID: 25291128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'The way to a man's heart is through his gut microbiota'--dietary pro- and prebiotics for the management of cardiovascular risk.
    Tuohy KM; Fava F; Viola R
    Proc Nutr Soc; 2014 May; 73(2):172-85. PubMed ID: 24495527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the microbiota in the management of gastrointestinal and liver disease.
    Quigley EM; Monsour HP
    Rev Gastroenterol Peru; 2013; 33(2):139-44. PubMed ID: 23838941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transitioning from Microbiome Composition to Microbial Community Interactions: The Potential of the Metaorganism
    Deines P; Bosch TC
    Front Microbiol; 2016; 7():1610. PubMed ID: 27790207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options.
    Bonfrate L; Tack J; Grattagliano I; Cuomo R; Portincasa P
    Scand J Gastroenterol; 2013 Sep; 48(9):995-1009. PubMed ID: 23964766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of synthetic microbial consortia for gut microbiota modulation.
    Vázquez-Castellanos JF; Biclot A; Vrancken G; Huys GR; Raes J
    Curr Opin Pharmacol; 2019 Dec; 49():52-59. PubMed ID: 31430629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiome and skin diseases.
    Zeeuwen PL; Kleerebezem M; Timmerman HM; Schalkwijk J
    Curr Opin Allergy Clin Immunol; 2013 Oct; 13(5):514-20. PubMed ID: 23974680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies.
    Shanahan F; Quigley EM
    Gastroenterology; 2014 May; 146(6):1554-63. PubMed ID: 24486051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre.
    Hart AL; Hendy P
    Proc Nutr Soc; 2014 Nov; 73(4):452-6. PubMed ID: 25221893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.